Sonoma Pharmaceuticals Announces Dr. Chelsea Tripp to Serve as Strategic Adviser to Company’s Animal Healthcare Division
PETALUMA, Calif (PRWEB) September 19, 2017 -- Dr. Chelsea Tripp, DVM, MS, DACVIM, a board-certified veterinary oncologist, has agreed to serve as strategic adviser to the animal healthcare division of Sonoma Pharmaceuticals (NASDAQ: SNOA, warrants SNOAW). Dr. Tripp is founder of the Bridge Animal Referral Center (BARC) in Edmonds, Washington, which specializes in compassionate cancer care for pets which includes cancer staging, advanced diagnostics, electrochemotherapy, immunotherapy, hyperthermia, injectable and oral chemotherapy as well as advanced imaging procedures.
As a strategic adviser to Sonoma’s animal wellness division, Dr. Tripp will support the company’s veterinarian outreach efforts, which includes adoption of the company’s vet-strength MicrocynVS® topical skin, wound, ear and eye formulations by veterinarians, both domestic and abroad.
“Dr. Tripp is a renowned specialist in companion animal oncology,” said Dan McFadden, vice president of animal wellness for Sonoma Pharmaceuticals. “She brings a most enlightened and humanistic approach to dealing with cancer in pets. We are most fortunate to be able to work with someone of her stature—who intimately understands the animal wellness space, both as a veterinarian and as a pet owner herself.”
Dr. Tripp received her veterinary degree from the University of Missouri returning to start practicing in Seattle in 2005. She finished a residency in medical oncology with Washington State University in 2010 becoming a board-certified oncologist. In 2015, Dr. Tripp founded Veterinary Cancer Specialty Care and subsequently, in 2017, she transitioned this enterprise into BARC and relocated into a newly remodeled facility in Edmonds, Washington. BARC is described by Dr. Tripp to be ‘the Fred Hutchinson Cancer Center or Seattle Cancer Care Alliance for pets in the Seattle area,’ offering secondary and tertiary care via referrals from veterinary clinics and hospitals throughout the Pacific Northwest. Dr. Tripp’s vision is to serve as a comprehensive cancer center that provides cutting-edge treatments, educates pet owners and offers support in all aspects of the management of cancer in companion species. She is a national speaker on the novel therapy of electrochemotherapy and is determined to make this protocol available across the country, having helped train many other colleagues in this technique. Her other areas of interest include client education, hyperthermia, oncologic emergencies, clinical pathology, palliative care and improving the quality of life for end-stage cancer patients. She believes the human-animal bond is an amazing thing and loves getting to witness this aspect of her job on a daily basis.
“I am excited to be involved in clinical studies utilizing Microcyn Technology to address resistant infections related to animal oncology. BARC has already deployed Microcyn-based topical products in a variety of settings for our treatment protocols, and the results to date in wound care are extremely favorable,” said Dr. Tripp.
Dr. Tripp will be presenting the family of Microcyn-based animal healthcare products to multiple audiences of Japanese veterinarians at the University of Tokyo in November of this year.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at http://www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals® and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden(at)sonomapharma(dot)com
Dan McFadden, Sonoma Pharmaceuticals, +1 (425) 753-2105, [email protected]
Share this article